A new study carried out by the scientists of the Gladstone Institutes led by the senior researcher Katerina Akassoglou, Ph.D., shows that many of the new drugs currently being tested may not be sufficient to promote repair within the toxic environment of these cells and identifies a different treatment option that could improve myelin repair.
The study, conducted in collaboration with theUC San Diego and the University of Vienna, in Austria, was published in the magazine Brain.
New drugs for multiple sclerosis: here’s what the research says
In those affected by multiple sclerosis, the fatty substance that insulates the nerves of the central nervous system, called myelin, is damaged. This slows the transmission of signals from the brain to the rest of the body, causing movement difficulties, vision problems and cognitive changes.